DV
Dividend Vision

IPSC — Century Therapeutics, Inc.

Century Therapeutics, Inc. (IPSC)

Total return is -91.6% over the past 5.2 years, 191.8 points behind SPY at 100.2%. Its deepest 1-year drawdown was 37.0%.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies for solid tumors, blood cancers, and autoimmune diseases, with lead candidates including an iPSC-derived beta islet cell therapy for type 1 diabetes and CAR-engineered cell therapies for B-cell autoimmune conditions. The company does not currently have a distribution. This security appeals to investors seeking exposure to early-stage biotechnology development with a focus on cellular immunotherapy approaches.

IPSC key facts

Asset type
Stock
Asset class
Equity
Inception date
06/18/2021
Distribution frequency
None
Last close
$1.92
Market cap
$347,664,608
Average volume
489965.0
Beta
1.602
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.93